Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SEA-BCMA |
Synonyms | |
Therapy Description |
SEA-BCMA is a humanized antibody against BCMA, which may increase antibody-dependent cellular cytotoxicity and cellular phagocytosis and decrease proliferation, potentially leading to decreased tumor growth (Cancer Res July 1 2018 (78) (13 Supplement) 3833). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SEA-BCMA | TNFRSF17 Antibody 20 | SEA-BCMA is a humanized antibody against BCMA, which may increase antibody-dependent cellular cytotoxicity and cellular phagocytosis and decrease proliferation, potentially leading to decreased tumor growth (Cancer Res July 1 2018 (78) (13 Supplement) 3833). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03582033 | Phase I | SEA-BCMA | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | Terminated | USA | 0 |